{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T16:08:33Z","timestamp":1787242113747,"version":"build-2736575974"},"reference-count":23,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2013,11,1]],"date-time":"2013-11-01T00:00:00Z","timestamp":1383264000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,11,1]],"date-time":"2013-11-01T00:00:00Z","timestamp":1383264000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2012,11,17]],"date-time":"2012-11-17T00:00:00Z","timestamp":1353110400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2013,11]]},"DOI":"10.1136\/annrheumdis-2012-202035","type":"journal-article","created":{"date-parts":[[2012,11,17]],"date-time":"2012-11-17T21:35:43Z","timestamp":1353188143000},"page":"1777-1785","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":80,"title":["Clinical efficacy, radiographic and safety findings through 2\u2005years of golimumab treatment in patients with active psoriatic arthritis: results from a long-term extension of the randomised, placebo-controlled GO-REVEAL study"],"prefix":"10.1016","volume":"72","author":[{"given":"Arthur","family":"Kavanaugh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iain B","family":"McInnes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip J","family":"Mease","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald G","family":"Krueger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dafna D","family":"Gladman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D\u00e9sir\u00e9e","family":"van der Heijde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Surekha","family":"Mudivarthy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weichun","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Mack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenhua","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Beutler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1136\/annrheumdis-2012-202035_bib1","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1136\/ard.2011.150995","article-title":"A systematic literature review of drug therapies for the treatment of psoriatic arthritis: current evidence and meta-analysis informing the EULAR recommendations for the management of psoriatic arthritis","volume":"71","author":"Ash","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2012-202035_bib2","doi-asserted-by":"crossref","first-page":"428","DOI":"10.4161\/mabs.12304","article-title":"Characterization of golimumab, a human monoclonal antibody specific for human tumor necrosis factor \u03b1","volume":"2","author":"Shealy","year":"2010","journal-title":"mAbs"},{"key":"10.1136\/annrheumdis-2012-202035_bib3","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1002\/art.23383","article-title":"Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate: a randomized, double-blind, placebo-controlled, dose-ranging study","volume":"58","author":"Kay","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1136\/annrheumdis-2012-202035_bib4","doi-asserted-by":"crossref","first-page":"2272","DOI":"10.1002\/art.24638","volume":"60","author":"Emery","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1136\/annrheumdis-2012-202035_bib5","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1136\/ard.2008.099010","article-title":"Golimumab, a human antibody to tumour necrosis factor \u03b1 given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study","volume":"68","author":"Keystone","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2012-202035_bib6","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1136\/ard.2009.116319","article-title":"Golimumab in patients with active rheumatoid arthritis despite methotrexate therapy: 52-week results of the GO-FORWARD study","volume":"69","author":"Keystone","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2012-202035_bib7","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/S0140-6736(09)60506-7","article-title":"Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor \u03b1 inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial","volume":"374","author":"Smolen","year":"2009","journal-title":"Lancet"},{"key":"10.1136\/annrheumdis-2012-202035_bib8","doi-asserted-by":"crossref","first-page":"3402","DOI":"10.1002\/art.23969","article-title":"Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial","volume":"58","author":"Inman","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1136\/annrheumdis-2012-202035_bib9","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1002\/art.24403","article-title":"Golimumab, a new human tumor necrosis factor \u03b1 antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: twenty-four-week efficacy and safety results of a randomized, placebo-controlled study","volume":"60","author":"Kavanaugh","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1136\/annrheumdis-2012-202035_bib10","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1002\/art.34436","article-title":"Golimumab, a human TNF-alpha antibody, administered every 4\u2005weeks as a subcutaneous injection in psoriatic arthritis: clinical efficacy, radiographic, and safety findings through 1\u2005year of the randomized, placebo-controlled, GO-REVEAL\u00ae study","volume":"64","author":"Kavanaugh","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1136\/annrheumdis-2012-202035_bib11","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1002\/art.1780380602","article-title":"American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis","volume":"38","author":"Felson","year":"1995","journal-title":"Arthritis Rheum"},{"key":"10.1136\/annrheumdis-2012-202035_bib12","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/art.1780380107","article-title":"Modified disease activity scores that include twenty-eight-joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis","volume":"38","author":"Prevoo","year":"1995","journal-title":"Arthritis Rheum"},{"key":"10.1136\/annrheumdis-2012-202035_bib13","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1136\/ard.2007.084459","volume":"68","author":"Wells","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2012-202035_bib14","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/art.1780350105","article-title":"Biannual radiographic assessments of hands and feet in a three-year prospective followup of patients with early rheumatoid arthritis","volume":"35","author":"van der Heijde","year":"1992","journal-title":"Arthritis Rheum"},{"key":"10.1136\/annrheumdis-2012-202035_bib15","doi-asserted-by":"crossref","first-page":"ii61","DOI":"10.1136\/ard.2004.030809","article-title":"Psoriatic arthritis imaging: a review of scoring mehods","volume":"64","author":"van der Heijde","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2012-202035_bib16","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1159\/000250839","article-title":"Severe psoriasis\u2014oral therapy with a new retinoid","volume":"157","author":"Fredriksson","year":"1978","journal-title":"Dermatologica"},{"key":"10.1136\/annrheumdis-2012-202035_bib17","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1002\/art.1780230202","article-title":"Measurement of patient outcome in arthritis","volume":"23","author":"Fries","year":"1980","journal-title":"Arthritis Rheum"},{"key":"10.1136\/annrheumdis-2012-202035_bib18","first-page":"789","article-title":"The dimensions of health outcomes: the health assessment questionnaire, disability and pain scales","volume":"9","author":"Fries","year":"1982","journal-title":"J Rheumatol"},{"key":"10.1136\/annrheumdis-2012-202035_bib19","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1136\/ard.62.2.127","article-title":"Assessment of enthesitis in ankylosing spondylitis","volume":"62","author":"Heuft-Dorenbosch","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2012-202035_bib20","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1067\/S0190-9622(03)00910-1","article-title":"Nail Psoriasis Severity Index: a useful tool for evaluation of nail psoriasis","volume":"49","author":"Rich","year":"2003","journal-title":"J Am Acad Dermatol"},{"key":"10.1136\/annrheumdis-2012-202035_bib21","author":"National Cancer Institute"},{"issue":"Suppl 1","key":"10.1136\/annrheumdis-2012-202035_bib22","first-page":"391","article-title":"How much improvement in functional status is considered important by patients with active psoriatic arthritis: applying the outcome measures in rheumatoid arthritis clinical trials (OMERACT) group guidelines. Abstract presented at EULAR 2004","volume":"63","author":"Mease","year":"2004","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2012-202035_bib23","doi-asserted-by":"crossref","first-page":"321","DOI":"10.2165\/11587890-000000000-00000","article-title":"The long-term safety of adalimumab treatment in moderate to severe psoriasis: a comprehensive analysis of all adalimumab exposure in all clinical trials","volume":"12","author":"Leonardi","year":"2011","journal-title":"Am J Clin Dermatol"}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724213108?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724213108?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/annrheumdis-2012-202035","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,14]],"date-time":"2025-02-14T03:48:04Z","timestamp":1739504884000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003496724213108"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,11]]},"references-count":23,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2013,11]]}},"alternative-id":["S0003496724213108"],"URL":"https:\/\/doi.org\/10.1136\/annrheumdis-2012-202035","relation":{},"ISSN":["0003-4967"],"issn-type":[{"value":"0003-4967","type":"print"}],"subject":[],"published":{"date-parts":[[2013,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical efficacy, radiographic and safety findings through 2\u2005years of golimumab treatment in patients with active psoriatic arthritis: results from a long-term extension of the randomised, placebo-controlled GO-REVEAL study","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/annrheumdis-2012-202035","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2022 \u00a9 Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by Elsevier Inc. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}